$ABT · ABBOTT LABORATORIES SEC Filings
Position Tracker tracks 11 SEC EDGAR filings for ABBOTT LABORATORIES ($ABT) from July 1, 2026 through November 4, 2026, including 0 Form 10-K annual reports, 2 Form 10-Q quarterly earnings reports, 2 Form 8-K current event disclosures, and 7 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$ABT 10-Q — ABBOTT LABORATORIES
A major acquisition-driven quarter shows Abbott growing the top line while earnings compress sharply, with a Nutrition spin-off reshaping the portfolio.
$ABT 4 — Abbott Laboratories
The filing is a Form 4 statement of changes in beneficial ownership for John A. McCoy Jr., who is identified as Vice President and Controller of Abbott Laboratories. It reports…
$ABT 4 — Abbott Laboratories
Abbott Laboratories filed a Form 4 with the Securities and Exchange Commission on September 3, 2026, reporting a change in beneficial ownership by Philip P. Boudreau, the compan…
$ABT 4 — Abbott Laboratories
On August 27, 2026, Abbott Laboratories filed a Form 4 with the SEC reporting changes in beneficial ownership by Robert B. Ford, the company’s Chairman and Chief Executive Offic…
$ABT 8-K — Abbott Laboratories
On August 20, 2026, Abbott Laboratories filed a Form 8-K disclosing that it entered into agreements to settle a portion of litigation involving its specialty formulas for preter…
$ABT 4 — Abbott Laboratories
This SEC Form 4 filing reports changes in beneficial ownership for Louis H. Morrone, an Executive Vice President of Abbott Laboratories. It discloses two transactions involving…
$ABT 10-Q — Abbott Laboratories
Abbott Laboratories filed its quarterly report on Form 10-Q for the period ended June 30, 2026. The filing covers the second quarter and first six months of fiscal 2026 and incl…
$ABT 8-K — Abbott Laboratories
On July 16, 2026, Abbott Laboratories filed a Form 8-K announcing its results of operations for the second quarter of 2026. The filing includes a press release issued the same d…
$ABT 4 — Abbott Laboratories
On July 1, 2026, Abbott Laboratories filed a Form 4 for director John G. Stratton. The filing reports that on June 30, 2026, Stratton acquired 432 stock equivalent units, bringi…
$ABT 4 — Abbott Laboratories
A Form 4 filed with the SEC on July 1, 2026 reports a change in beneficial ownership for Michael F. Roman, a director of Abbott Laboratories. On June 30, 2026, Roman acquired 41…
$ABT 4 — Abbott Laboratories
The filing is a Securities and Exchange Commission Form 4 reporting a change in beneficial ownership by Patricia Paola Gonzalez, a director of Abbott Laboratories. It discloses…